Despite current advances in antiemetic treatments, between 30% to and 60% of oncology patients experience chemotherapy-induced nausea (CIN) and 13% to 33% report chemotherapy-induced vomiting (CIV). Inter-individual differences are observed in the occurrence and severity of chemotherapy-induced nausea and vomiting (CINV). This review summarizes and critiques studies on associations between occurrence and severity of CINV and polymorphisms in serotonin receptor, drug metabolism, and drug transport pathway genes. Sixteen studies evaluated the associations between the occurrence and/or severity of CINV and single nucleotide polymorphisms (SNPs). Across these studies, three SNPs in 5-hydroxytryptamine receptor (5-HT3R) genes, two alleles of the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, and three SNPs in ATP binding cassette subfamily B member 1 (ABCB1) gene were associated with the occurrence and severity of CINV. Given the limited number of polymorphisms evaluated, additional research is warranted to identify new mechanisms to develop more targeted therapies.
Introduction
Despite current advances in antiemetic treatments, between 30% to 60% of oncology patients experience chemotherapy-induced nausea (CIN) and 13.3% to 32.5% report chemotherapy-induced vomiting (CIV) (National Comprehensive Cancer Network (NCCN), 2017; Cohen et al., 2007; Bloechl-Daum et al., 2006) . Despite the use of guideline directed antiemetic regimens, CIN continues to be one of the most severe side effects of chemotherapy (CTX) (Hofman et al., 2004) . Interindividual differences are observed in the occurrence and severity of chemotherapy-induced nausea and vomiting (CINV). Phenotypic characteristics associated with increased risk of CINV include: age under 50 years, female gender, higher trait anxiety, a history of motion sickness, a history of morning sickness, decreased alcohol intake, dehydration, malnutrition, recent surgery, and receipt of radiation therapy (Janelsins et al., 2013; Warr et al., 2011; Hesketh et al., 2010; Molassiotis et al., 2014) .
Treatment characteristics associated with increased risk for CINV include: higher pretreatment expectations for CINV; susceptibility to conditioned responses triggered by odors and tastes in the oncology clinic; occurrence of CINV during a previous CTX treatment; and feelings of warmth, dizziness, or lightheadedness after CTX (Molassiotis et al., 2016; Roscoe et al., 2011) . In addition, the intrinsic emetogenic potential of the CTX is an important factor that contributes to the occurrence and severity of CINV (Basch et al., 2011; Hesketh et al., 2016; Grunberg et al., 2005; Hesketh et al., 1997) . Finally, lack of adherence with the antiemetic regimen during and following CTX increases the risk for CINV (Molassiotis et al., 2014) .
While these phenotypic characteristics help to identify high risk patients, they do not explain all of the inter-individual variability in the occurrence and severity of CINV. For example, in a study of risk factors for antiemetic failure (Sekine et al., 2013) , 46% of the patients with three risk factors (i.e., female gender, younger age, no history of alcohol use) and 9% of the patients with no risk factors experienced antiemetic treatment failure. Recent evidence suggests that polymorphisms in genes involved in the nausea and vomiting pathways may influence oncology patients' risk for CINV and/or their responses to antiemetics. To date, four reviews have summarized findings from studies on associations between antiemetic efficacy and genetic polymorphisms in oncology patients receiving CTX (Trammel et al., 2013; Perwitasari et al., 2011a; Sugino and Janicki, 2015; Kiernan, 2016) .
In the first review (Perwitasari et al., 2011a) , findings from six pharmacogenetic studies of antiemetic efficacy were summarized. The specific genes evaluated across these six studies were: 5-hydroxytryptamine 3A receptor (HTR3A), HTR3B, HTR3C, ATP binding cassette subfamily B member 1 (ABCB1), and cytochrome P450 family 2 subfamily D member 6 (CYP2D6). The second review focused on an evaluation of differences in the efficacy of 5HT3 receptor antagonists associated with a number of genetic polymorphisms (Trammel et al., 2013) . While focused on a single mechanism, this review extended the findings from the previous review (Perwitasari et al., 2011a ) with a summary of four additional studies. The third review focused on the phamacogenetics of CINV (Sugino and Janicki, 2015) . This 2015 review was organized using the major mechanisms that contribute to antiemetic efficacy. Across nine studies, seven of which were highlighted in the previous reviews (Trammel et al., 2013; Perwitasari et al., 2011a) , associations between antiemetic efficacy and polymorphisms in HTR3B, HT3RC, HT3RD, neurokinin-1 (NK-1) receptor, ABCB1, organic cation transporter protein (OCT1), and CYP2D6 genes were described.
In the fourth narrative review that focused on the nursing implications of the pharmacogenomic studies of antiemetic efficacy (Kiernan, 2016) , only one additional study was summarized. The major focus of all four papers was to summarize the pharmacogenomic findings within the context of the major mechanisms that are targeted by antiemetics to decrease CINV, namely: 5HT3, drug transport, and drug metabolism pathways.
However, none of these reviews provided a comprehensive synthesis of these studies that included a detailed description of the associations between genetic polymorphisms and the occurrence and severity of CINV; a critique of the studies' designs and the methods used to assess CINV; a description of study limitations; and directions for future research. Therefore, the purposes of this review of the relationships between genetic polymorphisms and CINV are to: 1) describe salient study characteristics; 2) summarize and critique the instruments used to assess CINV and the timing of the assessments; 3) synthesize findings on associations between the occurrence and severity of CINV and genetic polymorphisms; and 4) synthesize findings on associations between antiemetic efficacy and genetic polymorphisms.
Methods

Literature search
A systematic electronic literature search was conducted using three databases: PubMed ® , Excerpta Medica Database (EMBASE ® ), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL ® ). A combination of keywords used to identify relevant studies were: chemotherapy-induced nausea and vomiting or chemotherapy-induced vomiting or chemotherapy-induced nausea AND gene or genetics or polymorphisms or gene expression or candidate genes. Studies were included if they met the following criteria: (1) the entire sample had a cancer diagnosis; (2) oncology patients were assessed for CIN and/or CIV; (3) oncology patients were genotyped; and (4) associations between the occurrence and/or severity of CIN and/or CIV, with or without antiemetic drugs, and patient genotype were described. An additional inclusion criterion was that the studies were published in English between 2000 and 2016 because the human genome was sequenced in 2000. Studies were excluded: (1) if the timing of the CIN or CIV assessments was not reported; (2) if they evaluated postoperative nausea and vomiting or radiotherapy-induced nausea and vomiting; and (3) if genotype associations were evaluated only in the context of the pharmacokinetics of the CTX. As shown in Fig. 1 , the search strategy yielded 202 studies in PubMed ® , 476 studies in EMBASE ® , and 12 studies in CINAHL ® . A total of 623 studies were excluded because the majority of them did not evaluate CINV. Of the 51 studies that did evaluate CINV, 35 were excluded because: 11 did not report the timing of the CIN or CIV assessment; 4 evaluated postoperative nausea and vomiting or radiotherapyinduced nausea and vomiting; 5 did not have genotype data; 1 evaluated genetic associations in the context of CTX pharmacokinetics; and 14 were review articles. These review articles had the following foci: one was on associations between postoperative nausea and vomiting and genetic polymorphisms; five focused on the protein structure of receptors involved in CINV; four described the pathophysiology of CINV and pharmacological interventions; and the four summarized above (Trammel et al., 2013; Perwitasari et al., 2011a; Sugino and Janicki, 2015; Kiernan, 2016) , described associations between antiemetic efficacy and genetic polymorphisms. Duplicate articles across the databases were removed and screened based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) criteria (Moher et al., 2009) . Based on our pre-specified inclusion criteria, sixteen studies are included in this review (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Tzvetkov et al., 2012; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Pud et al., 2014; Zoto et al., 2015) .
Data synthesis
These sixteen studies were summarized using the following prespecified evaluation criteria: author, year, purpose, and study design; emetogenicity of the CTX regimen; major study outcome(s); gene(s) and associated polymorphism(s) classified by function; sample characteristics (i.e., sample size, age, gender, diagnosis, treatment setting, antiemetic treatment); assessment of CINV (i.e., instrument(s), timing of CINV assessments); genotyping methods; statistical analyses; major findings; strengths; and limitations (Supplementary Table S1 ). Given the heterogeneity of the descriptive data among the studies in terms of sample characteristics, assessment of CINV, timing of CINV assessments, types of genotyping methods, specific polymorphisms evaluated, and the types of CTX, the results are summarized in tabular and narrative form.
Results
Sample and treatment characteristics
Study characteristics − All sixteen studies used a prospective cohort design. While all sixteen studies recruited patients from the outpatient setting, four included hospitalized patients (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Perwitasari et al., 2011b) . Six studies were conducted in Germany (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Fasching et al., 2008; Hammer et al., 2010; Tzvetkov et al., 2012) , two in the United States (Lamba et al., 2014; Lee et al., 2014) , two in Turkey (Babaoglu et al., 2005; Zoto et al., 2015) , and one each in China (He et al., 2014) , Japan (Tsuji et al., 2013) , Indonesia (Perwitasari et al., 2011b) , Israel (Pud et al., 2014) , Australia (Ward et al., 2008) , and Spain (Fernandez-Rozadilla et al., 2013) .
Patient characteristics − Sample sizes ranged from 64 (Tsuji et al., 2013) to 2886 (Lee et al., 2014) patients. Six had less than 200 patients (Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Tsuji et al., 2013; Lamba et al., 2014; Pud et al., 2014) . Across twelve studies that reported patients' age (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Perwitasari et al., 2011b; Tzvetkov et al., 2012; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Pud et al., 2014; Zoto et al., 2015) , the weighted grand mean age was 54.8 years. Of the remaining four studies, one did not report the patients' age (Ward et al., 2008) and three reported an age range (Hammer et al., 2010) , a median age (Lamba et al., 2014) , or both (Lee et al., 2014) . Across fourteen studies, the weighted grand mean percentage of female patients was 51.1%. Two studies did not report the patients' gender distribution (Ward et al., 2008; Tzvetkov et al., 2012) . When the study with 2886 patients was removed (Lee et al., 2014) , the grand mean percentage of females was 64.3%.
Across the 16 studies, various cancer diagnosis were included (e.g., breast cancer, lung cancer, non-small cell lung cancer, lymphoma, myeloma, ovarian cancer, nasopharyngeal cancer, vulvar cancer, cervical cancer, colorectal cancer, gastrointestinal cancer, genitourinary cancer). In six studies (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Tzvetkov et al., 2012; Zoto et al., 2015) , between 27.6% and 63.0% of the patients had breast cancer. In four studies (Fasching et al., 2008; Hammer et al., 2010; Tsuji et al., 2013; Pud et al., 2014) , 100% of the patients had breast cancer. In two studies (Fernandez-Rozadilla et al., 2013; Lee et al., 2014) , 100% of the patients had stage III or higher colon cancer. In one study (He et al., 2014) , all of the patients had acute myeloid leukemia. In another study (Lamba et al., 2014) , all of the patients had non-small cell lung cancer. One study did not report the patients' cancer diagnoses (Ward et al., 2008) .
Types of CTX − In nine studies (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Hammer et al., 2010; Tsuji et al., 2013; Pud et al., 2014; Zoto et al., 2015) , across a total of 1657 patients, 865 received cyclophosphamide alone or a combination CTX regimen that included cyclophosphamide. In seven studies (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Perwitasari et al., 2011b; Lamba et al., 2014; Zoto et al., 2015) , across a total of 1501 patients, 615 received a platinum-based CTX treatment. In two studies (Fernandez-Rozadilla et al., 2013; Lee et al., 2014) , 3903 patients received 5-flurouracil (5-FU) or a 5-FU based CTX regimen (e.g., a combination of folinic acid, 5-FU, and oxaliplatin (FOLFOX); a combination of folinic acid and 5-FU (FOLFIRI)). In one study of 216 patients (Babaoglu et al., 2005) , 161 received an anthracycline-based CTX regimen. In another study (He et al., 2014) , all 215 patients received cytarabine.
Emetogenicity of CTX regimens − Of the fourteen studies with available data, the CTX regimens were of moderate to high emetogenicity based on the classification scheme proposed by Hesketh and colleagues (Grunberg et al., 2011; Hesketh, 2008) . One study did not report on the emetogenicity of the CTX regimen (Ward et al., 2008) . One did not report the CTX regimen administered (Tzvetkov et al., 2012) .
Antiemetic treatment − Four studies did not report the specific antiemetic regimen administered (Fernandez-Rozadilla et al., 2013; Lamba et al., 2014; Lee et al., 2014; Pud et al., 2014) . In twelve studies (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Tzvetkov et al., 2012; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) , patients received serotonin antagonists prophylactically. In terms of the specific drugs, in ten studies, patients received a standardized regimen of tropisetron and/or ondansetron (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Tzvetkov et al., 2012; He et al., 2014) . In the remaining studies, patients received granisetron (Tsuji et al., 2013; Zoto et al., 2015) , dolasetron, (Ward et al., 2008) or metoclopramide (Perwitasari et al., 2011b) for delayed CINV. In five studies (Fasching et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Tsuji et al., 2013; Zoto et al., 2015) , dexamethasone was given with a standardized regimen that contained a serotonin antagonist.
Methods used to assess CIN and CIV
Assessment of CIN occurrence − The occurrence of CIN was evaluated in nine studies (Fasching et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Zoto et al., 2015) . In three studies (Fasching et Studies included in quantitative synthesis (n = 16) Fig. 1 . Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) flow diagram to determine studies on associations between chemotherapy-induced nausea and vomiting phenotypes and candidate gene polymorphisms. Reprinted with permission from (Moher et al., 2009). two of these studies (Fasching et al., 2008; Hammer et al., 2010) , patients documented the occurrence of CIN on an hourly basis for two days after the first cycle of CTX. In the third study (Tsuji et al., 2013) daily assessments of CIN were done for 5 days following CTX administration. Four studies (Perwitasari et al., 2011b; He et al., 2014; Lamba et al., 2014; Lee et al., 2014) used the National Cancer Institute Common Toxicity Criteria (NCICTC) to assess CIN occurrence. Three studies (Perwitasari et al., 2011b; He et al., 2014; Lee et al., 2014) used NCICTC version 3 and one study (Lamba et al., 2014) used NCICTC version 4. In two studies (Perwitasari et al., 2011b; He et al., 2014) , the occurrence of acute CIN was categorized as absent (i.e., grades 1 or 2) or present (i.e., grades 3 or 4). In the same two studies (Perwitasari et al., 2011b; He et al., 2014) , the occurrence of CIN was assessed using a visual analog scale (VAS) that ranged from 0 mm to 100 mm. CIN occurrence was categorized as absent (i.e., a score of < 5 mm on the VAS) or present (i.e., a score of > 5 mm on the VAS). In another study that used NCICTC version 3 (Lee et al., 2014) , patients were assessed biweekly for the occurrence of CIN, which was categorized as absent (i.e., grades 1 or 2) or present (i.e., grades 3 or 4).
In one study that used NCICTC version 4 (Lamba et al., 2014) , CIN occurrence was self-reported at the oncology clinic prior to CTX administration and before each subsequent cycle and was categorized as absent (i.e., grades 1 or 2) or present (i.e., grade 3). Other instruments used to assess the occurrence of CIN included the World Health Organization (WHO) toxicity grading scale (Fernandez-Rozadilla et al., 2013; WHO, 2017 ) and a daily questionnaire that rated the severity of CIN as none, slight, moderate, or severe (Zoto et al., 2015) . In the study that used the WHO toxicity grading scale (Fernandez-Rozadilla et al., 2013) , the timing of the CIN assessments was not reported. The occurrence of CIN was categorized as absent (i.e., WHO grades 1 or 2) or present (i.e., WHO grades 3 or 4). For the study that used the daily questionnaire (Zoto et al., 2015) , occurrence of CIN was assessed for five consecutive days from the start of CTX administration.
Of the nine studies that assessed the occurrence of CIN (Fasching et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; FernandezRozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Zoto et al., 2015) , only three reported its occurrence rate (Perwitasari et al., 2011b; Fernandez-Rozadilla et al., 2013; Lee et al., 2014) . The CIN occurrence rates were: 4.3% (Lee et al., 2014) , 21.8% (Perwitasari et al., 2011b) , and 23.3% (FernandezRozadilla et al., 2013) and the grand mean percentage rate was 9.9%.
Assessment of CIN severity − Six studies evaluated the severity of CIN (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Ward et al., 2008; Pud et al., 2014) . In three studies (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004) , CIN severity was assessed using a VAS (i.e., no nausea (0 mm) to the most extensive nausea (100 mm)) before CTX administration, between 0 and 4 h, and between 5 and 24 h after CTX administration. In one study (Babaoglu et al., 2005) , the severity of CIN was rated using a Likert scale (i.e., 0 = none, 1 = mild, 2 = moderate, 3 = severe), between 0 and 24 h and between 2 and 5 days after CTX. While one study used NCICTC version 3 to assess CIN severity (Ward et al., 2008) , the timing of the assessment was not reported (Ward et al., 2008) . In one study (Pud et al., 2014) , the Memorial Symptom Assessment Scale (MSAS) was used to assess the severity of CIN once in seven days for each cycle of CTX administration.
Of the six studies that assessed the severity of CIN (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Ward et al., 2008; Pud et al., 2014) , four reported its severity (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Pud et al., 2014) . Across three studies that used a VAS, (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004 ) the weighted grand mean average CIN severity score was 12.7 for the observation period between the 5th hour and the 24th hour after CTX administration. In the study that used the MSAS (Pud et al., 2014) , the average CIN severity for 105 patients was 1.7.
Assessment of CIV occurrence − Fourteen studies evaluated the occurrence of CIV (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Zoto et al., 2015) . Three of these studies had patients report the number of vomiting and retching episodes in a daily diary immediately before CTX administration, between 0 and 4 h, and between 5 and 24 h after CTX administration (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004) . In the six studies that used a diary to assess the occurrence of CIV (Babaoglu et al., 2005; Fasching et al., 2008; Hammer et al., 2010; Tzvetkov et al., 2012; Tsuji et al., 2013; Zoto et al., 2015) , patients completed the diary for 24 h (Tzvetkov et al., 2012) or for 5 days (Babaoglu et al., 2005; Tsuji et al., 2013; Zoto et al., 2015) following CTX administration. In two studies, (Fasching et al., 2008; Hammer et al., 2010) patients documented any CIV event on an hourly basis for two days following CTX administration.
Of the five studies that used the NCICTC to assess CIV occurrence, four (Ward et al., 2008; Perwitasari et al., 2011b; He et al., 2014; Lee et al., 2014) used version 3 and one (Lamba et al., 2014) used version 4. In four of these studies, (Ward et al., 2008; Perwitasari et al., 2011b; He et al., 2014; Lee et al., 2014 ) the occurrence of acute CIV was categorized as absent (i.e., grades 1 or 2) or present (i.e., grades 3 or 4). In two studies, (Perwitasari et al., 2011b; He et al., 2014) based on patient documentation of any vomiting episode, delayed CIV was dichotomized as "yes" or "no". In these two studies (Perwitasari et al., 2011b; He et al., 2014) , the occurrence of CIV was assessed daily for 5 days after CTX administration. In a third study (Ward et al., 2008) , CIV occurrence was assessed for 24 h following CTX administration. In the fourth study that used NCICTC version 3 (Lee et al., 2014) , CIV occurrence was assessed biweekly. In the study that used NCICTC version 4 (Lamba et al., 2014) , the occurrence of CIV was assessed at the oncology clinic prior to CTX administration and before each subsequent cycle. The occurrence of acute CIN was categorized as absent (i.e., grades 1 or 2) or present (i.e., grade 3).
Of the fourteen studies that evaluated the occurrence of CIV, ten reported its occurrence (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; FernandezRozadilla et al., 2013; Lee et al., 2014) . These occurrence rates ranged from 18.6% 26 to 40.0% 24 and the grand mean percentage was 14.2%.
Assessment of CIV severity − In the one study that used the MSAS to evaluate the severity of CIV (Pud et al., 2014) , it was assessed once in seven days for each cycle of CTX. CIV severity scores ranged from 0.0 ( ± 0.0) to 0.3 ( ± 0.7) with an average score of 0.25.
Analysis of genetic polymorphisms
Genotyping methods and statistical analyses − A variety of methods were used to identify genetic polymorphisms. Eight studies used restriction fragment length polymorphism (RFLP) and real time polymerase chain reaction (PCR) techniques to detect single nucleotide polymorphisms (SNPs) (Kaiser, 2002; Babaoglu et al., 2005; Fasching et al., 2008; Perwitasari et al., 2011b; Tzvetkov et al., 2012; Tsuji et al., 2013; Pud et al., 2014; Zoto et al., 2015) . Other techniques used were: automated capillary DNA sequencing (Tremblay et al., 2003; Kaiser et al., 2004) , multiplex PCR primer extension (Ward et al., 2008) , MegaBACE 1000 sequencer (Hammer et al., 2010) , genotyping microarray (Fernandez-Rozadilla et al., 2013) , and mass spectrometry (He et al., 2014; Lamba et al., 2014; Lee et al., 2014) .
Across the sixteen studies, Chi square analysis was the predominant method used to evaluate for associations between a CINV phenotype and genotype (Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Lee et al., 2014) . For multivariate analyses, logistic regression was used in six studies (Tremblay et al., 2003; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lee et al., 2014; Zoto et al., 2015) . Three studies used one-way analysis of variance (ANOVA) to evaluate for differences in CINV characteristics with respect to specific polymorphisms (Babaoglu et al., 2005; Tzvetkov et al., 2012; Pud et al., 2014) . Two studies performed a Kaplan Meier log rank test (Fasching et al., 2008; Hammer et al., 2010) , two conducted a Cox proportional hazard regression analysis (Fasching et al., 2008; Lamba et al., 2014) , and one performed the CochranMantel-Haenzel test (Tsuji et al., 2013) to determine associations between genetic polymorphisms and antiemetic responses. Fourteen out of the sixteen studies evaluated Hardy Weinberg equilibrium (Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Tzvetkov et al., 2012; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Pud et al., 2014; Zoto et al., 2015) .
Associations between CIN and genetic polymorphisms
Associations between the occurrence of CIN and genetic polymorphisms − As shown in Table S1 , nine studies evaluated for associations between the occurrence of CIN and a number of genetic polymorphisms (Fasching et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Zoto et al., 2015) . The specific genes evaluated included: HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E (Fasching et al., 2008; Hammer et al., 2010) ; ABCB1 (Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Zoto et al., 2015) ; ATP binding cassette subfamily C member 1 (ABCC1), ATPase copper transporting beta (ATP7B), and ATP binding cassette subfamily G member 2 (ABCG2) (Lamba et al., 2014) ; CYP2D6 (Perwitasari et al., 2011b) ; dihydropyrimidine dehydrogenase (DPYD) (Lee et al., 2014) ; and general transcription factor IIE subunit 1 (GTF2E1) (Lamba et al., 2014) . In the two studies that evaluated for associations between the occurrence of CIN and polymorphisms in a number of serotonin receptor genes (Fasching et al., 2008; Hammer et al., 2010) , no associations were found with any of the SNPs in HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E.
Five studies evaluated for associations between the occurrence of CIN and polymorphisms in ABCB1 (Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Zoto et al., 2015) . In the three studies that assessed rs1045642 (Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) , two found an association with the occurrence of CIN (He et al., 2014; Zoto et al., 2015) . Compared to patients who were homozygous or heterozygous for the common C allele, patients who were homozygous for the rare T allele had a decreased occurrence of CIN.
In two (He et al., 2014; Zoto et al., 2015) of the three studies that assessed for an association between the occurrence of CIN and ABCB1 rs20325282 (Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) , compared to patients who were homozygous for the common G allele, patients who were heterozygous (GT/A) or homozygous for the rare allele (TT/A) had a decreased occurrence of CIN (p = 0.012 and p = 0.021, respectively). In the third study (Tsuji et al., 2013) , patients who were homozygous for the rare T allele in this SNP were at increased risk for CIN (p = 0.045).
In the two studies that assessed for associations between the occurrence of CIN and ABCB1 rs1128503 (Lamba et al., 2014; Zoto et al., 2015) , only one found that being homozygous for the rare C allele was associated with an increased occurrence of acute CIN (p = 0.027) (Zoto et al., 2015) . In one of the five studies that assessed ABCB1, a haplotype analysis was done (Perwitasari et al., 2011b) . Patients with the CTT haplotype for three SNPs in the ABCB1 gene (i.e., rs1045642, rs20325282, rs1128503) experienced a decreased occurrence of acute CIN. However, this association did not reach significance (p = 0.07). In addition, compared with other ABCB1 haplotypes, patients with the CTG haplotype experienced an increased occurrence of delayed CIN (p = 0.02) (Perwitasari et al., 2011b) . In one study (Lamba et al., 2014) , no associations were found between the occurrence of CIN and two SNPs in ABCC1 (i.e, rs246240, rs2238476). However, patients with missense mutations in ATP7 B rs1801244 (i.e., valine to leucine change) and ABCG2 rs2231142 (i.e. glutamine to lysine change) were at an increased risk for CIN (p = 0.027 and p = 0.045 respectively).
In the one study that assessed for an association between the occurrence of CIN and polymorphisms in the drug metabolizing enzyme gene CYP2D6 (i.e., rs16947, rs3892097, rs1065852) (Perwitasari et al., 2011b) , no associations were found (p = 0.12). In another study that assessed for an association between the occurrence of CIN and a polymorphism in the DPYD enzyme gene (Lee et al., 2014) , patients with a splice donor variant in DPYD*2A rs3918290 (c.1905 + 1 G > A) were at an increased risk for CIN (p = 0.007). In a different study (Lamba et al., 2014) , that assessed for an association between CIN and a polymorphism in the intronic region of the transcription factor GTF2E1 gene (rs447978, specific allele not reported), patients had a 78% decrease in odds of experiencing CIN (OR (dominant model) = 0.22, 95% CI = −2.52 to −0.49, p = 0.004). In a genome wide association study (GWAS) that evaluated a number of adverse events associated with the administration of CTX (Fernandez-Rozadilla et al., 2013) , no polymorphisms were found that were associated with the occurrence of CIN.
Associations between the severity of CIN and genetic polymorphisms − As shown in Table S1 , six studies evaluated for associations between the severity of CIN and polymorphisms in HTR3A (Kaiser et al., 2004) , HTR3B (Tremblay et al., 2003) ; HTR3C (Ward et al., 2008; Pud et al., 2014) ; ABCB1 (Babaoglu et al., 2005) ; catecholamine-o-methyltransferase enzyme (COMT) (Pud et al., 2014) ; CYP2D6 (Kaiser, 2002; Tremblay et al., 2003) ; and guanidine triphosphate cyclohydrolase I (GCH1) (Pud et al., 2014) . Of the four studies that evaluated for associations between the severity of CIN and polymorphisms in serotonin receptor genes (Tremblay et al., 2003; Kaiser et al., 2004; Ward et al., 2008; Pud et al., 2014) , three (Tremblay et al., 2003; Kaiser et al., 2004; Ward et al., 2008) found no associations for any polymorphisms in HTR3A, HTR3B, and HTR3C. In one study (Pud et al., 2014) , being homozygous for the rare C allele for HTR3C rs6766410 was associated with decreased severity of acute CIN (p = 0.04). The association between the severity of CIN and HTR3C rs6807362 was not significant (p = 0.08) (Pud et al., 2014) .
In the study that assessed for an association between CIN severity and ABCB1 rs1045642 (Babaoglu et al., 2005) , being homozygous for the common C allele was associated with more severe acute CIN (p = 0.044). In contrast, no association was found between CIN severity and COMT rs4818 (p value not reported) (Pud et al., 2014) . In one (Tremblay et al., 2003) of the two studies, that assessed for an association between the severity of CIN and the CYP2D6 ultrarapid metabolizer (UM) allele, patients who were carriers of this allele had an increased risk for more severe CIN (p = 0.03). In the second study (Kaiser, 2002) , a similar trend was found but did not reach statistical significance. In the study that evaluated for associations between CIN severity and polymorphisms in GCH1 (i.e., rs10483639, rs3783641, rs8007267) (Pud et al., 2014) , the results were not significant (p values not reported).
Associations between CIV and genetic polymorphisms
Associations between the occurrence of CIV and genetic polymorphisms − As shown in Table S1 , fourteen studies (Kaiser, 2002; Perwitasari et al., 2011b; Fernandez-Rozadilla et al., 2013; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Lee et al., 2014; Zoto et al., 2015) evaluated for associations between the occurrence of CIV and a number of polymorphisms in HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E (Tremblay et al., 2003; Kaiser et al., 2004; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010) In two studies (Kaiser et al., 2004; Hammer et al., 2010) , no associations were found between the occurrence of CIV and polymorphisms in HTR3A (i.e., rs1062613, rs1176722, rs1176719, rs2276303, rs909411, rs1176713). In one study, (Tremblay et al., 2003) being homozygous for −100_-102AAG deletion variant in HTR3 B was associated with increased episodes of CIV (p < 0.02). In one (Fasching et al., 2008) of the two studies that evaluated for associations between the occurrence of CIV and polymorphisms in HTR3C, patients who were homozygous for rare C allele in rs6766410 had a shorter time to first emetic event. In the second study (Ward et al., 2008) , none of the seven SNPs in HTR3C demonstrated a significant relationship with the occurrence of CIV. In another study (Hammer et al., 2010) , no associations were found between the occurrence of CIV and polymorphisms in HTR3D (i.e., rs6443930, rs1000952) and HTR3E (i.e., rs5855015, rs7627615, rs56109847).
Six studies evaluated for associations between the occurrence of CIV and polymorphisms in drug transport pathway genes (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Zoto et al., 2015) . While five studies assessed ABCB1 rs1045642 (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) , only three (Babaoglu et al., 2005; He et al., 2014; Zoto et al., 2015) found an association with the occurrence of CIV. Being homozygous for the rare T allele in rs1045642 was associated with a decreased occurrence of acute CIV (p = 0.044, p = 0.002, and p = 0.016, respectively). Of the three studies that evaluated for an association between the occurrence of CIV and ABCB1 rs20325282 (Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) , in only one study (Tsuji et al., 2013) , being homozygous for the rare T allele was associated with an increased likelihood of reporting the occurrence of CIV (p = 0.045). In contrast, in the other two studies (He et al., 2014; Zoto et al., 2015) , being homozygous for the rare T allele in rs20325282 was associated with a decreased likelihood (Kaiser et al., 2004; Hammer et al., 2010) rs1176722 No association (Kaiser et al., 2004; Hammer et al., 2010) rs1176719 No association (Kaiser et al., 2004; Hammer et al., 2010) rs2276303 No association (Kaiser et al., 2004; Hammer et al., 2010) rs909411 No association (Kaiser et al., 2004; Hammer et al., 2010) rs1176713 No association (Kaiser et al., 2004; Hammer et al., 2010 ) CT haplotype (8046 T > C and 10627 G > T)
↓ CINV occurrence in tropisetron and ondansetron treated patients (Kaiser et al., 2004 ) HTR3B rs45460698 No association (Hammer et al., 2010; Perwitasari et al., 2011b) rs1176744 No association (Fasching et al., 2008) rs4938058 No association (Fasching et al., 2008; Perwitasari et al., 2011b) rs7943062 No association (Fasching et al., 2008; Perwitasari et al., 2011b ) HTR3C rs6766410 ↑ CIV episodes associated with rare allele in ondansetron and dexamethasone treated patients (Fasching et al., 2008) rs6807362 No association (Fasching et al., 2008) No association (Perwitasari et al., 2011b) rs1065852 No association (Perwitasari et al., 2011b ) UM (CYP2D6*1 + duplicate allele) ↑ CINV occurrence in tropisetron and ondansetron treated patients with three active alleles (Kaiser, 2002; Tremblay et al., 2003 ) PM (Two alleles of CYP2D6*3 CYP2D6*4 CYP2D6*5 CYP2D6*6) ↓ CINV occurrence and ↑ serum tropisetron concentration in patients with no active alleles (Kaiser, 2002) Abbreviations: ↑ = measured increased antiemetic efficacy, ↓ = measured decreased antiemetic efficacy, A = adenine, ABCB1 = ATP binding cassette subfamily B member 1, C88R = cysteine88-to-arginine, C = Cytosine, CINV = chemotherapy-induced nausea and vomiting, CIV = chemotherapy-induced vomiting, CYP2D6 = cytochrome P450 family 2 subfamily D member 6, G = guanine, G401S = glycine401-to-serine, G465R = glycine465-to-arginine, HTR3A = 5-hydroxytryptamine 3A receptor, HTR3B = 5-hydroxytryptamine 3 B receptor, HTR3C = 5-hydroxytryptamine 3C receptor, HTR3D = 5-hydroxytryptamine 3D receptor, HTR3E = 5-hydroxytryptamine 3E receptor, M420del = deletion of methionine420, OCT1 = organic cation transporter protein, PM = poor metabolizers, R61C = arginine61-to-cysteine, T = thymine, UM = ultrarapid metabolizer.
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Critical Reviews in Oncology / Hematology 121 (2018) [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] of CIV (p = 0.038 and p = 0.021). Two studies evaluated for an association between the occurrence of CIV and ABCB1 rs1128503 (Lamba et al., 2014; Zoto et al., 2015) . While in one study, no association was found (Lamba et al., 2014) , in the second study being homozygous or heterozygous for the rare C allele was associated with an increased number of episodes of vomiting (p = 0.027) (Zoto et al., 2015) . In another study (Perwitasari et al., 2011b) , patients who were carriers of the CTG haplotype in ABCB1 (i.e., rs1045642, rs20325282, rs1128503) experienced an increased occurrence of delayed CIV (p = 0.02). In another study (Lamba et al., 2014) , no associations were found between the occurrence of CIV and polymorphisms in a number of drug transport pathway genes (i.e., ABCC1 rs246240 and rs2238476, ABCG2 rs2231142, ATP7 B rs1801244).
Two studies evaluated for associations between the occurrence of CIV and polymorphisms in the drug metabolizing enzyme gene CYP2D6 (Kaiser, 2002; Perwitasari et al., 2011b) . While in one study, no association was found (Perwitasari et al., 2011b) , in the second study (Kaiser, 2002) , patients who were carriers of the UM allele for CYP2D6 experienced an increased occurrence of acute CIV (p < 0.03).
One study investigated the association between the occurrence of CIV and a DPYD polymorphism. Patients with the splice donor variant DPYD*2A rs3918290 (c.1905 + 1 G > A) were at an increased risk for the occurrence of CIV (p = 0.007) (Lee et al., 2014) . In the only study that evaluated for an association between the occurrence of CIV and a polymorphism in transcription factor gene GTF2E1 (Lamba et al., 2014) , no association was found with rs447978 (specific allele not reported). In a GWAS study (Fernandez-Rozadilla et al., 2013) , no significant associations were found with the occurrence of CIV.
Association between the severity of CIV and genetic polymorphisms − One study evaluated for associations between the severity of CIV and a number of genetic polymorphisms in 5-HTR3C, COMT, and GCH1 genes (Pud et al., 2014) . No associations were found between the severity of CIV and polymorphisms in HTR3C rs6766410 and rs6807362, COMT rs4818, and GCH1 rs10483639, rs3783641, rs8007267 (Pud et al., 2014) .
Associations between antiemetic efficacy and genetic polymorphisms
As shown in Table 1 , twelve studies evaluated for associations between the efficacy of antiemetics and polymorphisms in HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E (Tremblay et al., 2003; Kaiser et al., 2004; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b) ; ABCB1 (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) ; CYP2D6 (Kaiser, 2002; Tremblay et al., 2003; Perwitasari et al., 2011b) ; and OCT1 (Tzvetkov et al., 2012) .
In two studies (Kaiser et al., 2004; Hammer et al., 2010) , no associations were found between antiemetic efficacy and polymorphisms in HTR3A. In one study that included a haplotype analysis (Kaiser et al., 2004) , patients who were carriers of a CT haplotype in HTR3A (rs IDs not reported) were less likely to experience CIV and CIN with prophylactic antiemetic treatment (p = 0.01). In four studies (Tremblay et al., 2003; Fasching et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b) , no associations were found between antiemetic efficacy and polymorphisms in HTR3 B (rs1176744, rs45460698, rs4938058, rs7943062). In the two studies that assessed for an association between antiemetic efficacy and polymorphisms in HTR3C (Fasching et al., 2008; Ward et al., 2008) , only one (Fasching et al., 2008) found that patients who were homozygous for the rare C allele in HTR3C rs6766410 had a shorter time to first emetic event within 24 h of CTX administration (p = 0.002).
One study evaluated the association between antiemetic efficacy and polymorphisms in HTR3D and HTR3E (Hammer et al., 2010) . Being homozygous for the rare C allele for HTR3D rs6443930 was associated with an increased likelihood of responding to serotonin antagonists (p = 0.048) (Hammer et al., 2010) . No associations were found between antiemetic efficacy and polymorphisms in HTR3E (rs5855015, rs7627615, rs56109847).
Six studies evaluated for associations between antiemetic efficacy and polymorphisms in drug transport pathway genes (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tzvetkov et al., 2012; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) . Five studies evaluated for associations between antiemetic efficacy and polymorphisms in ABCB1 (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) . In one study (Babaoglu et al., 2005) , granisetron treated patients who were carriers of the rare T allele for ABCB1 rs1045642 had a higher likelihood of a complete response in the acute phase. In another study of granisetron treated patients (Tsuji et al., 2013) , being homozygous or heterozygous for the rare T/A allele for ABCB1 rs20325282 was associated with a lower complete response rate in the acute phase. In another study of granisetron treated patients (Zoto et al., 2015) , carriers of the TTT haplotype in ABCB1 (i.e., rs1045642, rs20325282, rs1128503) had a higher complete response rate. In the same study, this finding was not observed in the ondansetron treated patients (Zoto et al., 2015) . In two studies of patients treated with ondansetron (Perwitasari et al., 2011b; He et al., 2014) , carriers of the CTG haplotype in ABCB1 (i.e., rs1045642, rs20325282, rs1128503) (Perwitasari et al., 2011b) or carriers of the CG haplotype in ABCB1 (i.e., rs1045642, rs20325282) (He et al., 2014) experienced an increased incidence of CIN and CIV.
One study evaluated for an association between antiemetic efficacy and polymorphisms in OCT1 (Tzvetkov et al., 2012) . An in vitro assay demonstrated that polymorphisms in OCT1 with amino acid substitutions (i.e., R61C, C88R, G401S, M420del, G465R) abolished tropisetron uptake. Plasma concentrations of tropisetron at 3 h and 6 h after administration and of ondansetron at 3 h after administration were highest in patients who lacked a fully active OCT1 allele (p < 0.05). Patients who lacked an active OCT1 allele demonstrated a greater complete response (p = 0.007). This study controlled for the confounding effect of CYP2D6 allele.
Three studies evaluated for associations between antiemetic efficacy and polymorphisms in the drug metabolizing enzyme gene CYP2D6 (Kaiser, 2002; Tremblay et al., 2003; Perwitasari et al., 2011b) . While in one study (Perwitasari et al., 2011b) , no association was found in the other two studies (Kaiser, 2002; Tremblay et al., 2003) , patients who were carriers of three active CYP2D6 alleles (i.e., UMs) experienced decreased complete control of CIN and CIV after tropisetron and ondansetron administration. In one study (Kaiser, 2002) , patients with no active allele for CYP2D6 (i.e., poor metabolizers (PMs)) had significantly higher serum concentrations of tropisetron and demonstrated greater complete control of CIN and CIV than patients with three active CYP2D6 alleles (p < 0.03).
Discussion
This comprehensive review summarizes findings from sixteen studies that evaluated for associations between the occurrence and/or the severity of CINV, as well as antiemetic efficacy, and polymorphisms in a variety of candidate genes. As shown in Tables S1 and Table 1 , the majority of these genes were selected because they are involved in the mechanisms of CINV or in the major drug transport or drug metabolism pathways.
Serotonin pathway and CINV
Across the four CINV phenotypes (i.e., CIN occurrence and severity, CIV occurrence and severity), polymorphisms in five serotonin receptor genes were evaluated. This pathway was chosen because serotonin plays a major role in the development of CINV. Serotonin is released from enterochromaffin cells in the visceral mucosa following the administration of CTX. Serotonin activates 5-HT3 receptors on the vagus nerve which stimulates the medial nucleus of the solitary tract (NTS) and the dorsal vagal complex (DVC) in the medulla. This stimulation of the NTS and DVC signals vagal efferent fibers to produce retro-peristaltic contractions in the intestine and contractions in the stomach followed by relaxation of the gastric fundus and the lower esophageal sphincter. This action leads to expulsion of stomach contents (Darmani and Ray, 2009 ).
The 5-HT3 receptor is a ligand gated ion channel that is made up of five subunits (i.e., HTR3A, HTR3B, HTR3C, HTR3D, HTR3E) (Niesler et al., 2008) . The serotonin antagonists selectively block the excitation of presynaptic 5-HT3 receptors on the vagus nerve and act on the area postrema to block afferent signals from the vagus nerve that result in CINV (Darmani and Ray, 2009; Jordan et al., 2014) .
As shown in Table S1 , across six studies (Tremblay et al., 2003; Kaiser et al., 2004; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Pud et al., 2014 ) that evaluated 22 SNPs in the serotonin receptor pathway, only one found an association between CIN severity (Pud et al., 2014) and two found an association with CIV occurrence (Tremblay et al., 2003; Fasching et al., 2008) . For CIN severity, patients who were homozygous for rare C allele, in rs6766410 reported less severe CIN. This nonsynonymous SNP causes a change in the amino acid sequence from lysine to arginine which may alter the structure of the HTR3C receptor (Pud et al., 2014) . In another study (Fasching et al., 2008) , this SNP was associated with an increase in the occurrence of CIV. The other SNP associated with the increased occurrence of CIV was HTR3 B rs45460698 (Tremblay et al., 2003) . In one in vitro study (Meineke et al., 2008) , this deletion was associated with increased activity in the promoter region of HTR3B. However, these results need to be interpreted with caution because only 1.2% of the patients in the study had this polymorphism.
Drug transport pathway and CINV
Across the four CINV phenotypes, polymorphisms in four drug transport genes were evaluated. ABCB1 is a transmembrane glycoprotein that is present on the cell membrane of gastrointestinal (GI) tract enterocytes and on the endothelial cells of the cerebral cortex (Ishikawa et al., 2004) . ABCB1 limits intracellular absorption of CTX in the GI tract and restricts the entry of CTX into the central nervous system (CNS). Polymorphisms in ABCB1 may cause conformational changes in its protein structure and affect its function (Vivona et al., 2014) . This alteration may affect the absorption of CTX across the blood brain barrier which affects the occurrence and/or severity CINV.
ABCC1 and ABCG2 are transmembrane proteins that are part of the blood brain barrier and cause the efflux of CTX drugs such as taxanes (Lamba et al., 2014) . ATP7B is an ATPase expressed in the liver and kidney and to a lesser extent in the brain. Higher levels of ATP7B mRNA expression are correlated with higher rates of efflux and accumulation of CTX agents (i.e., carboplatin, cisplatin, oxaliplatin) in the bloodstream (Sprowl et al., 2013) . Polymorphisms in ABCC1, ABCG2, and ATP7B may change the rate of efflux of CTX drugs that enter the blood brain barrier and cause variations in occurrence and/or severity of CINV.
As shown in Table S1 , across six studies (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Zoto et al., 2015) , that evaluated seven SNPs and one haplotype in the drug transport pathway, five found associations with CIN occurrence (Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Lamba et al., 2014; Zoto et al., 2015) , one found an association with CIN severity (Babaoglu et al., 2005) , and five found associations with CIV occurrence (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) . The most consistent finding across the CINV phenotypes were for the ABCB1 gene. For ABCB1 rs1045642, patients who were homozygous for the rare T allele had a decrease in CIN (He et al., 2014; Zoto et al., 2015) and CIV (Babaoglu et al., 2005; He et al., 2014; Zoto et al., 2015) occurrence, as well as CIN severity (Babaoglu et al., 2005) . While this synonymous SNP does not change the amino acid sequence, it significantly decreases ABCB1 function (Zoto et al., 2015) .
The findings regarding ABCB1 rs20325282 are inconsistent. In two studies (He et al., 2014; Zoto et al., 2015) , the occurrence of both CIN and CIV were decreased in patients who were homozygous for the rare T allele. In another study (Tsuji et al., 2013) , the exact opposite associations were found. ABCB1 rs203252832 is a tri-allelic polymorphism where G is the common allele and A or T are the two possible rare variants. This nonsynonymous SNP causes a change in amino acid sequence from alanine to serine in the case of the rare A allele or threonine in the case of the rare T allele which may alter ABCB1 protein structure and/or function (Ishikawa et al., 2004) .
Only one study found a positive association between ABCB1 rs1128503 and the occurrence of CIN and CIV (Zoto et al., 2015) . While this synonymous SNP does not change the amino acid sequence of the protein, it may be in linkage disequilibrium with another SNP that affects ABCB1 function. In one study (Perwitasari et al., 2011b) , patients with the CTG haplotype in ABCB1 had an increase in the number of delayed CINV episodes. In a single study (Lamba et al., 2014) , that evaluated two nonsynonymous SNPs in different genes (i.e., ATP7B rs1801244, ABCG2 rs2231142), both SNPs were associated with an increase in CIN occurrence. While one SNP (ATP7B rs1801244) changes the amino acid sequence with no functional consequence (Lamba et al., 2014) , the other SNP (ABCG2 rs2231142) reduces ABCG2 efflux activity (Morisaki et al., 2005) .
Drug metabolism pathway and CINV
Across the four CINV phenotypes, only one drug metabolizing gene (i.e., CYP2D6) was evaluated. CYP2D6 belongs to a family of cytochrome P450 isoenzymes that bio-transforms drugs through oxidation. CYP2D6 is a heme containing membrane protein that is expressed in the liver, kidneys, and GI tract (Ogu and Maxa, 2000) . Approximately 5% to 10% of Caucasians lack the active CYP2D6 allele and as a result are PMs of drugs. Approximately 2% of Caucasians have more than 2 copies of active CYP2D6 allele and are UMs (Kaiser, 2002) .
As shown in Table S1 , across three studies (Kaiser, 2002; Tremblay et al., 2003; Perwitasari et al., 2011b) , that evaluated three SNPs and an UM polymorphism with more than two active copies of the gene as a result of duplication in CYP2D6, one found an association with CIN severity (Tremblay et al., 2003) and one with CIV occurrence (Kaiser, 2002) . Patients who had the UM CYP2D6 allele reported an increased severity of CIN and an increased occurrence of CIV. This finding suggests that these patients may have metabolized their antiemetics more rapidly (Kaiser, 2002) .
Antiemetic efficacy and genetic polymorphisms
As shown in Table 1 , across twelve studies (Kaiser, 2002; Tremblay et al., 2003; Kaiser et al., 2004; Babaoglu et al., 2005; Fasching et al., 2008; Ward et al., 2008; Hammer et al., 2010; Perwitasari et al., 2011b; Tzvetkov et al., 2012; Tsuji et al., 2013; He et al., 2014; Zoto et al., 2015) , associations between antiemetic efficacy and 24 SNPs and one haplotype in serotonin receptor genes, eight SNPs and one haplotype in two drug transport genes, and five alleles (i.e., including PM and UM) in drug metabolism pathways were evaluated. Three studies found associations between antiemetic efficacy and two SNPs and one haplotype in serotonin receptor genes (Kaiser et al., 2004; Fasching et al., 2008; Hammer et al., 2010) .
Most of the patients who had a CT haplotype in HTR3A and who were treated with tropisetron and ondansetron reported no CINV episodes. These two SNPs located in the intronic region of HTR3A have no known function (Kaiser et al., 2004) . In one study (Fasching et al., 2008) , patients who were homozygous for the rare C allele in HTR3C rs6766410 and were treated with ondansetron and dexamethasone were non-responders. This nonsynonymous SNP changes the amino acid sequence from lysine to asparagine in the cysteine-loop of the HTR3C receptor and may impair ondansetron binding to the serotonin receptor (Fasching et al., 2008) . In another study (Hammer et al., 2010) , patients who were homozygous for the rare C allele in HTR3D rs6443930 and treated with ondansetron and dexamethasone demonstrated increased antiemetic efficacy. This nonsynonymous SNP causes a change in the amino acid sequence from glycine to alanine near the Nterminus of the protein and may alter HTR3D protein structure (Hammer et al., 2010) .
Five studies found an association between drug transport pathway genes and antiemetic efficacy (Babaoglu et al., 2005; Perwitasari et al., 2011b; Tzvetkov et al., 2012; He et al., 2014; Zoto et al., 2015) . Patients who were homozygous for the rare T allele in ABCB1 rs1045642 and treated with granisetron reported a decrease in CINV (Babaoglu et al., 2005) . In another study (Tsuji et al., 2013) , patients who were homozygous for the rare T allele in ABCB1 rs20325282 and treated with granisetron reported increased CINV events. In one study (Zoto et al., 2015) , patients who were homozygous for rare C allele in ABCB1 rs1128503 and treated with granisetron reported increased CINV episodes. These SNPs may affect the level of ABCB1 gene expression or alter the structure of ABCB1 causing a change in granisetron binding to ABCB1 (Zoto et al., 2015) .
Patients with CG haplotype in ABCB1 rs1045642 and rs20325282 (He et al., 2014) or with TTT haplotype in ABCB1 rs1045642, rs20325282, and rs1128503 (Zoto et al., 2015) and treated with granisetron demonstrated less complete control in the case of the CG haplotype and higher complete control for the TTT haplotype. Patients with the CTG (Perwitasari et al., 2011b) or the TTT (Zoto et al., 2015) haplotypes in ABCB1 and treated with ondansetron experienced less complete control. Given that the half-life of ondansetron is shorter than granisetron this difference may contribute to the findings for carriers of TTT haplotype (Rao and Faso, 2012) . The role of CG and CTG haplotypes in decreased complete control is not clear (He et al., 2014; Zoto et al., 2015) .
One study investigated the role of OCT1 in the cellular uptake of tropisetron and ondansetron and its influence on the drug's therapeutic efficacy (Tzvetkov et al., 2012) . OCT1 is one of the most abundantly expressed drug transport genes in the liver. It synthesizes OCT1, a plasma membrane protein that is critical for the elimination of many endogenous small organic cations, drugs, and toxins (Chen et al., 2010) . Polymorphisms in the exon region of OCT1 were analyzed to determine if changes in the amino acid sequence could impact drug transport function and influence cellular uptake of these antiemetics (Tzvetkov et al., 2012) . The in vitro and in vivo data suggest that concentrations of ondansetron were highest in patients who lacked the active OCT1 allele and concentrations of ondansetron decreased with increases in the number of active OCT1 alleles. Patients who lacked an active OCT1 allele had higher plasma concentration of ondansetron and tropisetron. Patients who had active OCT1 alleles vomited more frequently.
Drug-drug interactions may influence OCT1 function and contribute to inter-individual variability in hepatic uptake of tropisetron and ondansetron. CTX drugs like oxaliplatin but not carboplatin are substrates for OCT1 (Tzvetkov et al., 2012) . Additional SNPs in OCT1 discovered recently may influence the loss of function of OCT1 (Chen et al., 2010) . Further investigation is required to understand the role of OCT1 in antiemetic efficacy.
In the two studies that found an association between drug metabolizing pathway genes and antiemetic efficacy, patients with three active CYP2D6 alleles referred to as the UM group who were treated tropisetron and ondansetron reported an increase in CINV episodes. In one study (Kaiser, 2002) , patients with no active CYP2D6 alleles, (i.e., PMs) and treated with tropisetron and ondansetron, reported a decreased number of CINV episodes. Since serum concentrations of tropisetron were highest in the PM group, it was considered a protective allele (Kaiser, 2002) .
Limitations of the sixteen studies
Sample size -Across the sixteen studies, the sample sizes ranged from 64 to 2886, with the majority of studies having a sample size of approximately 200 patients. None of the studies reported a power analysis based on the number of SNPs evaluated. Sample size selection for a candidate gene analysis depends on the number of SNPs analyzed, effect size of the SNPs, their allelic frequency, and the extent to which the SNPs are in linkage disequilibrium (Leschziner et al., 2007) . Of the 49 SNPs and one haplotype evaluated for associations with CINV, only 11 were statistically significant. Of the 37 SNPs and two haplotypes evaluated for associations with antiemetic efficacy, only 10 were statistically significant. One reason for the lack of consistent findings across the sixteen studies is the relatively small sample sizes.
Allelic frequencies for HTR3A, HTR3B, HTR3C, HTR3D, HTR3E, ABCB1, and CYP2D6 genes differ among various ethnic populations. While these sixteen studies were conducted in nine different countries, most of them did not report patients' ethnicity and none reported if ancestry informative markers (AIMs) were used to control for these differences. Again, the failure to control for genomic estimates of race/ ethnicity may contribute to the inconsistent findings. Most studies did not control for differences in phenotypic characteristics prior to the evaluation of associations between the various CINV phenotypes and genetic polymorphisms. In addition, most studies did not control for variations in the same gene.
Sample characteristics − Across the sixteen studies, patients varied in their cancer diagnoses. While in some studies, patients had a single cancer diagnosis, in other studies patients were heterogeneous in terms of their cancer diagnoses. Some studies recruited only female patients and one recruited only male patients. Across the sixteen studies, patients' ages ranged from 14 years to 86 years. The studies were rather diverse in the types of CTX, as well as the antiemetic regimens, that were evaluated. Diversity in sample characteristics across these studies may have contributed to the inconsistent findings.
CINV assessment − While a variety of instruments can be used to assess CINV, no gold standard assessment tool is available. While some instruments, like the Morrow Assessment for Nausea and Vomiting (MANE) assess the frequency and severity of acute and anticipatory CINV (Morrow, 1992) , others like the MASCC Antiemesis Tool (MAT) evaluate the occurrence and duration of acute and delayed CINV (Brearley et al., 2008) .
While these two valid and reliable CINV tools are available, neither was used in any of the sixteen studies in this review. The majority of the studies used a VAS, the NCICTC and/or a patient diary to assess one or more of the CINV phenotypes. None of the studies reported on the validity and reliability of the VAS or the patient diary. The NCICTC does not evaluate the frequency of CIN. NCICTC version 3 assesses CIN for the first 24 h and version 4 does not indicate the timing for the CIN assessment.
Conclusions
To date, between 13% to 60% of oncology patients experience CINV (National Comprehensive Cancer Network (NCCN), 2017; Cohen et al., 2007; Bloechl-Daum et al., 2006) . While sixteen studies have attempted to determine associations between various CINV phenotypes and polymorphisms in a number of candidate genes, very few definitive conclusions can be drawn from these data due to the limitations enumerated above. As noted in Table 2 , a number of areas warrant consideration in future research including adequately powered studies for the specific genomic analyses that are purposed; more rigorous phenotyping of CINV; evaluation of additional mechanisms that underlie CINV and antiemetic efficacy; and evaluation of changes in gene expression and epigenetics that contribute to the CINV phenotype and antiemetic efficacy. • Use valid and reliable instruments to characterize the CINV phenotypes (e.g.,
MANE)
• Determine the optimal timing for CINV measures to capture anticipatory, acute, and delayed CINV phenotypes. Mechanistic considerations for candidate gene selection
• Evaluate additional pathways involved in the development of CINV (e.g., NK-1 receptor, dopamine receptor activation pathways).
• Evaluate additional pathways involved in antiemetic efficacy (e.g., drug metabolizing enzyme pathways other than CYP2D6) Other types of genomic analyses
• Evaluate for changes in gene expression that contribute to anticipatory, acute and delayed CINV
• Evaluate for epigenetic changes that contribute to anticipatory, acute and delayed CINV Abbreviations: CINV = chemotherapy-induced nausea and vomiting, CYP2D6 = cytochrome P450 family 2 subfamily D member 6, MANE = morrow assessment for nausea and vomiting, NK-1 = neurokinin-1, SNPs = single nucleotide polymorphisms.
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